tirzepatide death SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I AHA 2024 - Tirzepatide lowers

Semaglutide is the active ingredient in medications used for patients with Type 2 diabetes

Fat loss, particularly in stubborn areas that resist diet and exercise alone, often becomes visible

Typical Timeline: First few days: Appetite suppression begins as the medication takes effect Weeks 1-4: Reduced caloric intake leads to initial weight loss Weeks 5-12: Steady weight loss continues, with most patients seeing 5% body weight loss by week 12 3-6 months: Many patients achieve 10% or more total body weight loss Plateau Management: Some patients experience plateaus, which is normal

Clinical trials showed that weight loss happens gradually with Wegovy